Published online Aug 31, 2010.
https://doi.org/10.5388/jkon.2010.10.2.231
Characteristics and Quality of Life in Patients with Chemotherapy-Induced Peripheral Neuropathy
Abstract
Purpose
The purpose of study was to identify how patients experienced chemotherapy-induced peripheral neuropathy (CIPN) and quality of life related to CIPN.
Methods
This was a descriptive research. We collected data from 105 patients with chemotherapy-induced peripheral neuropathy. They completed a self-reported questionnaire including Eastern Cooperative Oncology Group (EORTC) CIPN20 and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment.
Results
In the study, duration of peripheral neuropathy was 9.4 month and 54.3% of patients used pharmacological or non-pharmacological interventions. Patients reported the highest score for sensory scale and it's score was 38.74±20.24. The scores for motor scale and autonomic scale were 21.95±19.19 and 26.61±21.0 respectively. This showed that patients more suffered from sensory neuropathy than any other domain of neuropathy. The most frequently selected two items were 'did you have tingling fingers or hands?' and 'did you have tingling toes or feet?'.
Conclusion
The results of this study will provide useful information for chemotherapy-induced peripheral neuropathy.
Table 1
Characteristics of the patients (N=105)
Table 2
Characteristics related to peripheral neuropathy (N=105)
Table 3
Score and frequency per question of EORTC CIPN20
Table 4
The differences of CIPN20 by characteristics related to peripheral neuropathy (N=105)
Table 5
Correlation between characteristics related to peripheral neuropathy and CIPN20 (N=105)
References
-
Wilkes GM. In: Cancer symptom management. Boston: Jones and Bartlett; 1999. Neurologic disturbances.
-
-
Ellen ML, Susan LB, Jeffrey C. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2008;35:96–102.
-
-
Wickhan R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11:361–376.
-
-
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. 2009.Support Care in Cancer, Online first at http://www.springerlink.com/content/e958243151613358/.
-
-
Katsumasa K, Kojiro S, Yasuo O, Ayano T, Toshihiko A, Satoshi M, et al. A questionnaire survey of physicians' perspective regarding the assessment of chemotheraphy-induced peripheral neuropathy in patients with Breast cancer. Jpn J Clin Oncol 2008;38:748–754.
-
-
Diana D. Management of peripheral neuropathy caused by microtubule inhibitor. Clin J Oncol Nurs 2009;13:686–694.
-